Novo Nordisk to cap insulin prices in Minnesota settlement; joins Lilly, Sanofi
Novo Nordisk agreed to cap insulin prices to settle a lawsuit in which Minnesota's attorney general accused the three largest ...
FDA approves Novo Nordisk's diabetes drug Ozempic for chronic kidney disease, expanding use in U.S.
Ozempic’s expanded approval in the U.S. could transform how doctors treat patients with the condition, which involves a ...
US FDA approves Novo Nordisk's Ozempic to cut risk of diabetic kidney disease progression
The U.S. FDA has approved Novo Nordisk's Ozempic for reducing the risk of kidney failure and disease progression, as well as ...
Novo Nordisk’s Ozempic Gets FDA Approval as Kidney-Disease Treatment
Ozempic, or semaglutide, can now be used to reduce the risk of worsening kidney disease or kidney failure in adults with type ...
US FDA approves Novo Nordisk's Ozempic to reduce diabetic kidney disease progression
Ozempic belongs to a class of drugs known as GLP-1 receptor agonists and has the same active ingredient as the company's ...
Novo Nordisk Vaults Above LVMH as Europe’s Biggest Company
Good news about an experimental weight-loss shot sent shares in Ozempic maker Novo Nordisk soaring, making it once again ...
NBC Los Angeles6d
Novo Nordisk shares pop on early-stage weight loss drug trial results
The Danish pharmaceutical giant reported positive early-stage results for its once weekly amycretin obesity drug.
Novo Nordisk Stock Soars on New Weight-Loss Drug Results
Novo Nordisk stock jumped Friday after the Danish drugmaker announced new data for a new weight-loss drug which appeared to ...
Pharmaceutical Technology on MSN20h
Novo Nordisk secures FDA approval for Ozempic in diabetes with CKD
The new indication makes Ozempic the first glucagon-like peptide-1 receptor agonist (GLP-1RA) available for people with T2D ...
GlobalData on MSN2d
Novo Nordisk reports topline data from Phase Ib/IIa trial of weight loss therapy
Novo Nordisk has reported topline outcomes from a Phase Ib/IIa trial of amycretin designed for treating obese or overweight ...
US FDA approves Novo Nordisk's Ozempic to reduce risk of kidney diseases in diabetic patients
Breakthrough in diabetes treatment! The US FDA approves Ozempic for reducing kidney disease risk in diabetic patients. Learn ...
Novo Nordisk's SWOT analysis: obesity drug leader faces supply hurdles
A/S, a global healthcare giant specializing in diabetes care and obesity treatment, continues to dominate the GLP-1 drug market alongside competitor Eli Lilly (NYSE:LLY). With a market capitalization ...